Irreversible Electroporation Device Market – Global Market Size, Share, and Forecast 2026-2032
Global Leading Market Research Publisher QYResearch announces the release of its latest report, “Irreversible Electroporation Device – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032.” This comprehensive study provides an in-depth analysis of the global irreversible electroporation (IRE) device market, combining historical trends (2021–2025), current industry developments, and future projections through 2032. The report addresses the growing clinical demand for minimally invasive tumor ablation, precision oncology interventions, and bioelectrical therapy solutions in hospitals and research institutions worldwide.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6116136/irreversible-electroporation-device
Market Overview
The global market for irreversible electroporation devices was valued at US$ 148 million in 2025 and is projected to reach US$ 218 million by 2032, growing at a CAGR of 5.8%. Market growth is driven by the increasing adoption of minimally invasive ablation therapies, integration of image-guided navigation, and rising investment in interventional oncology and cardiac electrophysiology.
In 2024, the global production capacity reached approximately 950 units, with actual sales around 820 units, and an average selling price of USD 170,000 per unit. Gross margins ranged from 25% to 40%, reflecting the premium technology and high clinical value of these devices. In the past six months, demand has increased in North America and Europe due to expanded reimbursement policies for IRE procedures and the growing clinical preference for non-thermal ablation techniques that preserve adjacent healthy tissue.
Device Structure and Functional Applications
An irreversible electroporation device (IRE) is an advanced medical system that employs high-voltage pulsed electric fields to achieve precise non-thermal ablation of targeted tissues. Key operational principles include:
- Permanent nanopore formation in cell membranes, disrupting cellular homeostasis and inducing apoptosis
- Non-thermal ablation, minimizing collateral tissue damage compared to conventional thermal modalities
- Precision tissue remodeling, applicable in oncology and selected cardiac interventions
The system comprises:
- High-voltage pulse generators with voltage control modules
- Multi-channel electrode probes for targeted ablation
- Imaging guidance units for accurate probe placement
- Intraoperative monitoring and control software
- Industrial computing platforms and data analytics modules
Typical clinical applications include:
- Oncology Ablation: Treatment of liver, pancreatic, and prostate tumors, where thermal ablation risks damage to critical structures
- Cardiac Ablation: Treatment of arrhythmias with precise lesion formation while preserving surrounding myocardial tissue
- Other Medical Applications: Experimental bioelectrical therapies and research studies on tissue regeneration
Industry Chain Analysis
The IRE device market is structured into three main segments:
Upstream: Suppliers of high-voltage power modules, medical-grade electrodes (titanium or stainless steel), insulation materials, imaging/navigation components, and electronic control boards. Recent trends include modest increases in high-voltage component costs due to global supply chain constraints, particularly for titanium and precision electronics.
Midstream: Device manufacturers are responsible for assembling and integrating components, conducting dielectric and sterility testing, and ensuring regulatory compliance. Manufacturers are increasingly adopting discrete and modular production approaches, allowing scalability and flexibility to meet diverse clinical demands.
Downstream: End-users include oncology hospitals, tertiary medical centers, interventional radiology units, cardiac electrophysiology departments, and research institutions. The downstream segment dictates overall demand, which has been bolstered in the last six months by rising clinical adoption of IRE for hard-to-treat tumors and high-risk cardiac patients.
Cost Structure
The cost composition of IRE devices includes:
- Raw materials and electronic components: ~50–55%, driven by high-voltage modules, electrodes, and precision sensors
- Pulse power systems and control electronics: 15–20%
- Manufacturing, assembly, and quality control: 15–20%
- Software integration and imaging/navigation components: 7–10%
- Labor, testing, and overhead: 5–7%
The high upfront cost is balanced by clinical efficacy, reduced procedure times, minimized patient complications, and lower post-operative care costs, which are increasingly valued by hospital procurement departments.
Market Segmentation
By Type:
- Pulse Power Generators: Core energy delivery units with precision voltage control
- Electrode Probes: Multi-channel arrays for targeted tissue ablation
- Other Components: Imaging modules, software platforms, and intraoperative monitoring systems
By Application:
- Oncology Ablation: Largest segment, driven by rising global cancer incidence and demand for minimally invasive treatments
- Cardiac Ablation: Focused growth segment, particularly in atrial fibrillation and ventricular arrhythmia management
- Other Applications: Includes experimental bioelectrical therapies and tissue modulation research
Competitive Landscape
Leading manufacturers include: AngioDynamics, Pulse Biosciences, Surgnova, Alpmed, Shanghai Nortion Medical Technology, and Hangzhou Ready Biological Technology. Competitive differentiation is based on equipment precision, imaging integration, safety certification, and customer service, with recent product innovations emphasizing real-time monitoring, software-assisted probe positioning, and energy delivery optimization.
Market Outlook and Trends
Key growth drivers over the forecast period (2026–2032) include:
- Expansion of non-thermal, minimally invasive ablation protocols in oncology and cardiology
- Integration of image-guided navigation with IRE systems to enhance procedural accuracy
- Increased regulatory approvals and insurance reimbursement support in mature healthcare markets
- Rising adoption in tertiary hospitals and specialized research centers for experimental and therapeutic applications
Challenges include high equipment costs, component supply volatility, and complex regulatory requirements. Innovations in modular manufacturing, discrete component assembly, and enhanced software analytics are expected to improve efficiency and reduce unit costs over the next six years.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
